Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate

September 6, 2026

Endpoints News USA

Overview

Novartis has disclosed the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS) complications in clinical trials of its CAR-T cell therapy, rapcabtagene autoleucel (rap-cel), for autoimmune diseases. This led Novartis to temporarily suspend several immunology and neuroscience studies, a move mirrored by Bristol Myers Squibb with its zolacabtagene autoleucel (zola-cel) for autoimmune research. The incidents have ignited a crucial debate regarding the safety risks and acceptable tolerability of applying CAR-T therapies to autoimmune conditions.

In Depth

Background

CAR-T cell therapies have revolutionized cancer treatment, offering remarkable efficacy in certain hematological malignancies. Driven by these successes, researchers have explored their potential application in severe autoimmune diseases, where conventional treatments often fall short. However, the powerful immune-modulating effects that make CAR-T effective in cancer also pose significant safety challenges, especially when applied to non-lethal conditions.

Key Findings

Novartis confirmed three patient deaths in clinical trials evaluating its CAR-T cell therapy, rapcabtagene autoleucel (rap-cel), for autoimmune diseases.
The fatalities were attributed to complications arising from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS).
Following these safety concerns, Novartis has temporarily suspended several immunology and neuroscience research programs.
In a parallel development, Bristol Myers Squibb also paused its autoimmune research involving a similar CAR-T product, zolacabtagene autoleucel (zola-cel).

Significance & Outlook

The tragic patient deaths and subsequent trial suspensions by two major pharmaceutical companies underscore a critical juncture in the development of CAR-T therapies for autoimmune diseases. While the promise of these treatments is immense for patients with severe, refractory conditions, the emergence of fatal adverse events like IEC-HS necessitates a rigorous re-evaluation of the risk-benefit profile. The industry and regulatory bodies are now confronting complex questions about the acceptable level of risk for these powerful therapies when treating non-oncological conditions. This development will likely lead to enhanced safety monitoring protocols, refined patient selection criteria, and potentially modified CAR-T constructs or dosing regimens for autoimmune indications, ensuring a more cautious and data-driven approach moving forward.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGg9jl8oXzBuuBabhJTDaJqE0Kq2W2X2gSnLWnOWN3Cxm4BEHOyGn7AFRnmgHwFuc31ItrgFEQoGDvqu1Nl8ETZ7MIjkbYjbLtKDMeo6z7Sb0CPRC3vntANhQvOIj-YxXYC_JTeNBhuDyWX3OT74Aky1hVLghvbUsFTLeYQkNh6DZ_i3FFYn_xOHXxucLb3r0K5lA==

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.